ACCC In the Press at ASCO 2018

At the 2018 ASCO Annual Meeting, we had the opportunity to connect with many ACCC members and engage a wide audience! Oncology Business Review, OncLive, and ASCO Post sat down with a number of ACCC advocates and leaders to discuss pressing issues in cancer care.

ACCC Treasurer Randall A. Oyer, MD, with an update on the ACCC Immuno-Oncology Institute:

ACCC Immuno-Oncology Institute Executive Committee Member Ivo Abraham, PhD, RN, speaks about value in cancer care:

ACCC Past President Jennie R. Crews, MD, MMM, FACP, describes how care coordination in immunotherapy is engaging new providers with the cancer care team:

Dr. Abraham shares his perspective on hurdles to adoption of biosimilars in oncology:

Watch more from Dr. Abraham on:

Key features of a biosimilar - via OBR

Biosimilars approved and nearing approval for oncology - via OBR

Biosimilar pricing and reimbursement - via OBR

Dr. McBride Discusses financial toxicity in oncology with OncLive:

Lee S. Schwartzberg, MD, FACP, discusses how the ACCC Immuno-Oncology Institute is evolving to support integration of IO in the community through new working groups, resources for cross-specialty care coordination, and team education for this rapidly expanding field. - ASCO Post

Dr. Zibelman discusses managing immune-related adverse events with OncLive:

Posted 6/13/2018